Emergent BioSolutions Inc. (LON:0IGA)

Emergent BioSolutions Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	742.9	1,044	1,049	1,118	1,774
Revenue Growth (YoY)	-28.81%	-0.54%	-6.10%	-36.99%	12.45%
Cost of Revenue	326.2	681.3	705.4	693.1	748.1
Gross Profit	416.7	362.3	343.9	424.4	1,026
Selling, General & Admin	186.1	308	368.4	339.5	348.7
Depreciation & Amortization Expenses	65.1	65.1	65.6	59.9	58.5
Research & Development	53.2	70.7	111.4	188.3	235.2
Other Operating Expenses	12.2	27.2	524.9	6.7	41.7
Operating Income	100.1	-108.7	-726.4	-170	341.4
Interest Expense	-59.3	-71	-87.9	-37.3	-34.5
Other Non-Operating Income (Expense)	66.4	36.8	83.1	-11.7	-3.7
Total Non-Operating Income (Expense)	7.1	-34.2	-4.8	-49	-38.2
Pretax Income	82.8	-142.9	-731.2	-219	303.2
Provision for Income Taxes	30.2	47.7	29.3	-7.4	83.7
Net Income	52.6	-190.6	-760.5	-211.6	219.5
Net Income to Common	52.6	-190.6	-760.5	-211.6	219.5
Net Income Growth	-	-	-	-	-28.22%
Shares Outstanding (Basic)	54	53	51	50	54
Shares Outstanding (Diluted)	57	53	51	50	54
Shares Change (YoY)	6.98%	3.52%	2.20%	-7.39%	0.56%
EPS (Basic)	0.98	-3.60	-14.85	-4.22	4.10
EPS (Diluted)	0.93	-3.60	-14.85	-4.22	4.06
EPS Growth	-	-	-	-	-28.52%
Free Cash Flow	156.8	35.8	-257.9	-149.9	96.1
Free Cash Flow Growth	337.99%	-	-	-	-75.67%
Free Cash Flow Per Share	2.77	0.68	-5.04	-2.99	1.78
Gross Margin	56.09%	34.72%	32.77%	37.98%	57.82%
Operating Margin	13.47%	-10.42%	-69.23%	-15.21%	19.25%
Profit Margin	7.08%	-18.26%	-72.48%	-18.94%	12.38%
FCF Margin	21.11%	3.43%	-24.58%	-13.41%	5.42%
EBITDA	205.7	7.5	-580	-22.6	469.3
EBITDA Margin	27.69%	0.72%	-55.27%	-2.02%	26.46%
EBIT	100.1	-108.7	-726.4	-170	341.4
EBIT Margin	13.47%	-10.42%	-69.23%	-15.21%	19.25%
Effective Tax Rate	36.47%	-33.38%	-4.01%	3.38%	27.61%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.